SCHEMBL3352074

SCHEMBL3352074

O=C(O)c1ccc(-c2ccsc2)s1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.58
RAB9A P51151 2/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
ESRRG P62508 4/20 0.57
ALDH1A1 P00352 3/20 0.53
KDM4E B2RXH2 3/20 0.53
GAA P10253 2/20 0.53
ESR1 P03372 1/20 0.52
ESR2 Q92731 1/20 0.52
HPGDS O60760 1/20 0.51
MKNK1 Q9BUB5 1/20 0.51
MKNK2 Q9HBH9 1/20 0.51
PTPRF P10586 1/20 0.47
PTPN1 P18031 1/20 0.47
IKBKB O14920 1/20 0.45
MAPT P10636 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
HPGD P15428 1/20 0.45
NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27605052 0.87 ESRRG (0.59) POLBRAB9AMEN1KMT2AESRRG
SCHEMBL5877482 0.84 ESRRG (0.56) ESRRGALDH1A1KDM4EGAAESR1
SCHEMBL5991048 0.84 IKBKB (0.57) POLBRAB9AMEN1KMT2AESRRG
SCHEMBL20912454 0.80 ESRRG (0.42) POLBRAB9AMEN1KMT2AESRRG
SCHEMBL22068905 0.78 POLB (0.68) POLBRAB9AMEN1KMT2AALDH1A1
SCHEMBL593023 0.77 MEN1 (0.65) POLBRAB9AMEN1KMT2AALDH1A1
SCHEMBL1679991 0.77 CYP2A6 (0.50) ESRRGALDH1A1ESR1ESR2PTPRF
SCHEMBL1761545 0.76 RAB9A (0.92) POLBRAB9AMEN1KMT2AALDH1A1
SCHEMBL2247613 0.76 HDAC1 (0.69) POLBRAB9AMEN1KMT2AALDH1A1
SCHEMBL2615879 0.75 MEN1 (0.63) POLBRAB9AMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US claimed
US-20090170913-A1 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-07-02 US claimed
EP-1828177-B1 NOVEL MCH RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-08-13 EP claimed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US claimed
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives PHARMACIA & UPJOHN COMPANY 2004-09-02 US claimed
WO-2023074408-A1 THIOPHENE COMPOUND, METHOD FOR SYNTHESIZING SAME, AND COMPOSITION CONTAINING SAID THIOPHENE COMPOUND 四国化成工業株式会社 2023-05-04 WO disclosed
CN-110577512-B Preparation method of asymmetric structure 5-alkoxy-2, 3' -bithiophene and bromo-derivative 河南大学 2021-01-26 CN disclosed
CN-110577512-A Preparation method of asymmetric structure 5-alkoxy-2, 3' -bithiophene and bromo-derivative 河南大学 2019-12-17 CN disclosed
US-7838543-B2 Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles ELI LILLY AND COMPANY (US) 2010-11-23 US disclosed
US-20090170913-A1 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-07-02 US disclosed
EP-1828177-B1 NOVEL MCH RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-08-13 EP disclosed
EP-1828177-A2 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2007-09-05 EP disclosed
WO-2006066173-A2 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives BACE1, BACE2, PSEN1 POLB 747/4885RAB9A 1302/4885MEN1 2250/4885
US-20090170913-A1 NOVEL MCH RECEPTOR ANTAGONISTS MCHR1, MCHR2, MC1R POLB 4496/4885RAB9A 1154/4885MEN1 550/4885
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP POLB 2249/4885RAB9A 874/4885MEN1 2356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.